CIBC Bancorp USA’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding LCTX
CIBC Bancorp USA's LCTX Position: Q3 2026 in Review
CIBC Bancorp USA increased its Lineage Cell Therapeutics (LCTX) stake by 116% in Q3 2026, buying an estimated $13.1K and bringing the position to 22,018 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #2218.
CIBC Bancorp USA first reported a position in LCTX in Q2 2026 and has held it in 2 quarters since. 143 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.
- CIBC Bancorp USA held 22,018 shares of Lineage Cell Therapeutics worth $21K as of Q3 2026.
- CIBC Bancorp USA bought 11,844 Lineage Cell Therapeutics shares in Q3 2026, an estimated $13.1K.
- Lineage Cell Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #2218 holding.
- CIBC Bancorp USA first reported a position in Lineage Cell Therapeutics in Q2 2026 and has held it in 2 quarters since.
- 143 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.
Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.